<bvy class="pckrm"></bvy>

南宫NG28

Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer

2026-07-28

Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer

Akeso’s Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

2026-06-15

Akeso’s Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

Akeso’s Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfoli

2026-06-11

Akeso’s Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfoli

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

2026-05-31

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

Over 40 Studies Featuring Akeso’s Innovative Oncology Agents to Be Presented at ASCO 2026 : Ivonescimab’s HARMONi-6 Overall Survival Data Selected for Plenary Session

2026-05-26

Over 40 Studies Featuring Akeso’s Innovative Oncology Agents to Be Presented at ASCO 2026 : Ivonescimab’s HARMONi-6 Overall Survival Data Selected for Plenary Session

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026 HONG KONG, May 15, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European Hematology Association (EHA) Congress. The abstract is now available on the EH

2026-05-14

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026 HONG KONG, May 15, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European Hematology Association (EHA) Congress. The abstract is now available on the EH

Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

2026-04-28

Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026

2026-04-20

Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026

Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor–Resistant Advanced NSCLC at ELCC 2026

2026-04-07

Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor–Resistant Advanced NSCLC at ELCC 2026

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

2026-03-30

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

Akeso Reports Full-Year 2025 Financial Results

2026-03-27

Akeso Reports Full-Year 2025 Financial Results

Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab

2026-03-24

Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab

1 2 3 4 5 6 7 8 9 »